Factors influencing health behavior changes in people with early multiple sclerosis: process evaluation of the multicenter randomized controlled POWER@MS1 trial

影响早期多发性硬化症患者健康行为改变的因素:多中心随机对照 POWER@MS1 试验的过程评估

阅读:1

Abstract

BACKGROUND: Health behavior changes, i.e., optimizations of physical activity, diet, sleep and stress management, are increasingly considered as modifiers of prognostic risk in multiple sclerosis (MS). A personalized digital lifestyle management application ("levidex"), designed to support people with MS (pwMS) in coping with their diagnosis and adopting healthier behaviors, was evaluated against an active psychoeducational control program ("dexilev") in a randomized controlled trial (RCT; "POWER@MS1"). OBJECTIVES: This study evaluates the POWER@MS1 trial, focusing on the processes and organizational aspects of the study. Specifically, it seeks to (1) identify the contextual factors that influence behavior change in pwMS and (2) assess how the intervention and study design were perceived by pwMS and involved health care professionals (HCPs; neurologists, study nurses, radiologists). METHODS: A mixed methods approach was applied. During the study period questionnaire data were collected from all trial participants (n = 234) and HCPs (n = 91) and were analyzed quantitatively. After the RCT ended, semi-structured interviews were conducted with 15 HCPs and 16 pwMS. Participants were selected according to the maximum variation sampling. Data was analyzed thematically. RESULTS: Quantitative trial data revealed that the levidex group significantly agreed more to behavioral changes after 3 months [levidex (6.65); dexilev (5.23), p < 0.001]. Improvements in diet, physical activity and stress management were reported. PwMS considered evidence-based information, meditation instructions and self-monitoring tools embedded in levidex as particularly helpful. In the interviews, they reported close monitoring through regular clinical visits as reassuring after MS diagnosis. A healthy lifestyle was considered an important component of MS treatment by both HCPs and pwMS. Both perceived levidex as a useful addition to standard care, but reported a need for additional personal consultation. CONCLUSION: Health behavior change was rated as an important component of MS treatment. A digital application was perceived to be beneficial for the facilitation of relevant behavior change.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。